Deep Track Capital

Deep Track Capital is a Greenwich, Connecticut-based investment firm exclusively focused on the life sciences industry. The firm specializes in developing long-term partnerships with the management teams of innovative public and pre-IPO biotechnology companies. They aim to lead investment transactions while also participating in rounds led by other qualified investors, employing a fundamentally driven due diligence strategy to identify opportunities within the sector.

Founded in 2020 by David Kroin, who serves as the Chief Investment Officer, Deep Track Capital leverages his extensive experience of over 25 years in healthcare investing. Prior to establishing Deep Track Capital, Mr. Kroin co-founded Great Point Partners in 2003, where he co-managed an equity long/short biotechnology hedge fund and was an investment committee member for private equity funds focused on healthcare company recaps and buyouts.

The firm's investment portfolio includes a diverse range of biotechnology and life sciences companies. Notable investments have been made in companies such as LB Pharmaceuticals, ProMIS Neurosciences, Century Therapeutics, Solid Biosciences, enGene Holdings Inc, Vera Therapeutics, Inc., GRAIL, LLC, Soleno Therapeutics, Inc., and Verastem, Inc. Deep Track Capital also holds positions in publicly listed companies like Maze Therapeutics and Septerna, and has engaged in activist investment strategies, as seen with Dynavax Technologies Corporation.

The investment team at Deep Track Capital comprises seasoned professionals with deep expertise in healthcare finance and investment. Key members include Managing Directors Brett Erkman, Rebecca Luse, Rael Mazansky, MD/MBA, and Gerard Smith, MD/MBA, all bringing extensive backgrounds from prominent investment firms, sell-side research, and healthcare industry roles. Their collective experience spans venture capital, private equity, and public market investing, contributing to the firm's comprehensive approach to identifying and supporting promising life sciences ventures.